Although prospective clinical studies comparing standard (in mg/m2) versus individualized dosing have yet to be performed, it is likely that individualized dosing of some anti-cancer drugs, based on pharmaco-kinetics, could increase the probability of tumour response and decrease the probability of major toxicity. In the absence of routine therapeutic drug monitoring, adjustment of the dose of subsequent treatment cycles according to the presence or absence of toxicity should be implemented more systematically.

0 0

Post a comment